Radiation Oncology Unit, University Hospital S. Chiara, Pisa, Italy.
Eur Rev Med Pharmacol Sci. 2017 Nov;21(21):4882-4890.
To assess changes of CT perfusion parameters (ΔPCTp) of cervical lymph node metastases from head and neck cancer (HNC) before and after radiochemotherapy (RT-CT) and their association with nodal tumor persistence.
Eligibility criteria included HNC (Stage III-IV) candidates for RT-CT. Patients underwent perfusion CT (PCT) at baseline 3 weeks and 3 months after RT-CT. Blood volume (BV), blood flow (BF), mean transit time (MTT) and permeability surface (PS) were calculated. PET/CT examination was also performed at baseline and 3 months after treatment for metabolic assessment.
Between July 2012 and May 2016, 27 patients were evaluated. Overall, only 3 patients (11%) experienced tumor persistence in the largest metastatic lymph node. A significant reduction of all PCTp values (p<0.0001), except MTT (from 6.3 to 5.7 s; p=0.089), was observed at 3 weeks post-RT-CT compared to baseline. All PCTp values including MTT were significantly lower at 3-month follow-up compared to baseline (p<0.05). Moreover, a statistically significant association was observed between nodal tumor persistence and high BF values (p=0.045) at 3 months after treatment that did not occur for the other parameters.
Our preliminary findings show that all PCTp except MTT are significantly reduced after RT-CT. High BF values at 3 months post-RT-CT are predictive of nodal tumor persistence.
评估头颈部癌(HNC)颈淋巴结转移患者放化疗(RT-CT)前后 CT 灌注参数(Δ PCTp)的变化及其与淋巴结肿瘤残留的关系。
纳入标准为 HNC(III-IV 期)患者,适合 RT-CT。患者在 RT-CT 前、后 3 周和 3 个月时行灌注 CT(PCT)检查。计算血容量(BV)、血流量(BF)、平均通过时间(MTT)和通透性表面积(PS)。治疗前和治疗后 3 个月也进行了 PET/CT 检查,以进行代谢评估。
2012 年 7 月至 2016 年 5 月,共评估了 27 例患者。总体而言,仅 3 例(11%)患者在最大转移性淋巴结中出现肿瘤残留。与基线相比,RT-CT 后 3 周时所有 PCTp 值(p<0.0001)均显著降低,除 MTT(从 6.3 降至 5.7 s;p=0.089)外。与基线相比,所有 PCTp 值(包括 MTT)在 3 个月随访时均显著降低(p<0.05)。此外,在治疗后 3 个月,BF 值与淋巴结肿瘤残留之间存在统计学显著相关性(p=0.045),而其他参数则没有。
我们的初步发现表明,RT-CT 后除 MTT 外所有 PCTp 值均显著降低。RT-CT 后 3 个月时 BF 值高预示淋巴结肿瘤残留。